Latest News
8 October 2021 18-month results from the PRESTIGE Below-the-Knee (BTK) study have been presented as a Late Breaking Clinical Trial at VIVA21. The objective of this clinical investigation has been to evaluate safety and performance outcomes of SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, for the treatment of long tibial occlusive […]
12 August 2021 MedAlliance has announced completion of patient enrolment in the PRISTINE clinical trial with SELUTION SLR™ 018 DEB (drug-eluting balloon) for the treatment of patients with Below-the-Knee (BTK) disease. SELUTION SLR is the first DEB to be awarded “Breakthrough Device Designation” by the FDA. PRISTINE is a Prospective […]
NYON, Switzerland, Feb. 10, 2021 (PRNewswire) MedAlliance has announced enrolment of the first patient in SUCCESS PTA, its large post-market study with the drug-eluting balloon SELUTIONSLRTM for the treatment of patients with peripheral artery disease (PAD). SELUTION SLR is a novel sirolimus-eluting balloon that provides a controlled sustained release of […]
NYON, Switzerland, Jan. 28, 2021 (PRNewswire) 12-month results from the PRESTIGE Below-the-Knee (BTK) studyhave been presented as a Late Breaking Trial at LINC 2021. The objective of this clinical investigation has been toevaluate safety and performance outcomes of SELUTION SLRTM,MedAlliance’s novel sirolimus-eluting balloon, for thetreatment of long tibial occlusive lesions […]
July 10, 2020 (PRNewswire) MedAlliance has announced enrollment of the first patient in its study of SELUTION SLR™ 014 DEB for the treatment of In-Stent Restenosis (ISR). This is the first DEB accepted by the FDA for its “Breakthrough Program”. The SELUTION SLR (Sustained Limus Release) is a novel sirolimus […]
Copyright © BioIndia Services. All Rights Reserved.
